Koomdee Napatrupron, Kloypan Chiraphat, Jinda Pimonpan, Rachanakul Jiratha, Jantararoungtong Thawinee, Sukprasong Rattanaporn, Prommas Santirhat, Nuntharadthanaphong Nutthan, Puangpetch Apichaya, Ershadian Maliheh, John Shobana, Biswas Mohitosh, Sukasem Chonlaphat
Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
Front Pharmacol. 2022 Apr 5;13:866903. doi: 10.3389/fphar.2022.866903. eCollection 2022.
The is the most polymorphic gene, play a crucial role in drug-induced hypersensitivity reactions. There is a lot of evidence associating several risk alleles to life-threatening adverse drug reactions, and a few of them have been approved as valid biomarkers for predicting life-threatening hypersensitivity reactions. The objective of this present study is to present the progression of pharmacogenomics (PGx) testing in the Thai population during a 10-year period, from 2011 to 2020. This was a retrospective observational cohort study conducted at the Faculty of Medicine Ramathibodi Hospital. Overall, 13,985 eligible patients who were tested for risk alleles between periods of 2011-2020 at the study site were included in this study. The PGx testing has been increasing year by year tremendously, 94 testing was done in 2011; this has been raised to 2,880 in 2020. Carbamazepine ( = 4,069, 33%), allopurinol ( = 4,675, 38%), and abacavir ( = 3,246, 26%) were the most common drugs for which the genotyping was performed. and are highly frequent, and are moderately frequent alleles that are being associated with drug induced hypersensitivity. and theses alleles are rare but has been reported with drug induced toxicity. Most of the samples were from state hospital (50%), 36% from private clinical laboratories and 14% from private hospitals. According to this study, PGx testing is increasing substantially in Thailand year after year. The advancement of research in this field, increased physician awareness of PGx, and government and insurance scheme reimbursement assistance could all be factors. Incorporating PGx data, along with other clinical and non-clinical data, into clinical decision support systems (CDS) and national formularies, on the other hand, would assist prescribers in prioritizing therapy for their patients. This will also aid in the prediction and prevention of serious adverse drug reactions.
该基因是多态性最高的基因,在药物诱导的超敏反应中起关键作用。有大量证据表明,多个风险等位基因与危及生命的药物不良反应有关,其中一些已被批准作为预测危及生命的超敏反应的有效生物标志物。本研究的目的是呈现2011年至2020年这10年间泰国人群中该药物基因组学(PGx)检测的进展情况。这是一项在拉玛提波迪医院医学院进行的回顾性观察队列研究。总体而言,本研究纳入了2011年至2020年期间在研究地点接受该风险等位基因检测的13985名符合条件的患者。该PGx检测逐年大幅增加,2011年进行了94次检测;到2020年已增至2880次。卡马西平(n = 4069,33%)、别嘌醇(n = 4675,38%)和阿巴卡韦(n = 3246,26%)是进行该基因分型最常见的药物。某些等位基因高度常见,某些等位基因中等频率出现,且与药物诱导的超敏反应有关。还有一些等位基因罕见,但已报道与药物诱导的毒性有关。大多数样本来自国立医院(50%),36%来自私立临床实验室,14%来自私立医院。根据本研究,泰国的PGx检测逐年大幅增加。该领域研究的进展、医生对PGx认识的提高以及政府和保险计划的报销支持都可能是因素。另一方面,将PGx数据与其他临床和非临床数据纳入临床决策支持系统(CDS)和国家处方集,将有助于开处方者为患者确定治疗的优先顺序。这也将有助于预测和预防严重的药物不良反应。